00:00It's Benzinga, bringing Wall Street to Main Street.
00:02CVS Health reversed its decision to restrict access to Eli Lilly's obesity drug ZepBound
00:08after Lilly agreed to cut the price it charges many health plans, according to Bloomberg.
00:14Starting on October 1st, ZepBound and Novo Nordisk's Wagovi will carry equal co-pays
00:19on health plans using Caremark's standard formulary. CVS said the change is expected
00:25to save health plans 10% to 15% on obesity drug costs.
00:30Lilly's new weight loss pill foundeo will also gain coverage on certain plans starting June 1st,
00:36making it available through all three major pharmacy benefit managers.
00:39CVS had previously favored Wagovi under a deal struck with Novo Nordisk in July of last year,
00:45pushing patients toward the rival drug.
00:47Lilly's ZepBound sales reached $13.5 billion in 2025 and are projected to exceed that figure in 2026.
00:55For all things money, visit Benzinga.com.
Comments